{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:59:08Z","timestamp":1791651548037,"version":"4.3.4"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctrv.2022.102461","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T12:04:53Z","timestamp":1661861093000},"page":"102461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":308,"special_numbering":"C","title":["Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy"],"prefix":"10.1016","volume":"110","author":[{"given":"Yu","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K","family":"Nesline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"DePietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarabjot","family":"Pabla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102461_b0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2022.102461_b0010","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2022.102461_b0015","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2022.102461_b0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2022.102461_b0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2022.102461_b0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2022.102461_b0035","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39629","article-title":"Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sj\u00f6gren's Syndrome","volume":"68","author":"Maria","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ctrv.2022.102461_b0040","doi-asserted-by":"crossref","first-page":"e0130715","DOI":"10.1371\/journal.pone.0130715","article-title":"Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis","volume":"10","author":"Mancuso","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2022.102461_b0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","article-title":"The therapeutic potential of targeting tryptophan catabolism in cancer","volume":"122","author":"Opitz","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0050","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096906","article-title":"Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients","volume":"214","author":"Weinlich","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.ctrv.2022.102461_b0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.lungcan.2009.05.001","article-title":"Increased serum kynurenine\/tryptophan ratio correlates with disease progression in lung cancer","volume":"67","author":"Suzuki","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0065","doi-asserted-by":"crossref","unstructured":"Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008;206:849-54; discussion 54-6.","DOI":"10.1016\/j.jamcollsurg.2007.12.014"},{"key":"10.1016\/j.ctrv.2022.102461_b0070","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6603477","article-title":"Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer","volume":"95","author":"Ino","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0075","doi-asserted-by":"crossref","unstructured":"Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T, et al. Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell. 2018;33:480-94.e7.","DOI":"10.1016\/j.ccell.2018.02.005"},{"key":"10.1016\/j.ctrv.2022.102461_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.594098","article-title":"Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2022.102461_b0085","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2022.102461_b0090","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102461_b0095","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2022.102461_b0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2007.00470.x","article-title":"Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer","volume":"98","author":"Nakamura","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2022.102461_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.736498","article-title":"Clinical relevance of serum Kyn\/Trp ratio and basal and IFN\u03b3-upregulated IDO1 expression in peripheral monocytes in early stage melanoma","volume":"12","author":"Meireson","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2022.102461_b0110","doi-asserted-by":"crossref","first-page":"20768","DOI":"10.1073\/pnas.1009201107","article-title":"An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis","volume":"107","author":"Quintana","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2022.102461_b0115","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-07-4144","article-title":"Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival","volume":"14","author":"Ino","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1541-7786.MCR-18-0362","article-title":"A role for tryptophan-2,3-dioxygenase in CD8 T-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma","volume":"17","author":"Greene","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2022.102461_b0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.ctrv.2022.102461_b0135","doi-asserted-by":"crossref","first-page":"e87877","DOI":"10.1371\/journal.pone.0087877","article-title":"Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production","volume":"9","author":"Lowe","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2022.102461_b0140","doi-asserted-by":"crossref","unstructured":"Sadik A, Somarribas Patterson LF, \u00d6zt\u00fcrk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell. 2020;182:1252-70.e34.","DOI":"10.1016\/j.cell.2020.07.038"},{"key":"10.1016\/j.ctrv.2022.102461_b0145","doi-asserted-by":"crossref","first-page":"10678","DOI":"10.1021\/acs.jafc.0c03735","article-title":"Endogenous indole pyruvate pathway for tryptophan metabolism mediated by IL4I1","volume":"68","author":"Zhang","year":"2020","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.ctrv.2022.102461_b0150","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4049\/jimmunol.1502615","article-title":"Tolerogenic phenotype of IFN-\u03b3-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine\/AhR-IDO Loop","volume":"197","author":"Li","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2022.102461_b0155","doi-asserted-by":"crossref","first-page":"19961","DOI":"10.1073\/pnas.1014465107","article-title":"Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism","volume":"107","author":"Nguyen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2022.102461_b0160","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2012692118","article-title":"The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation","volume":"118","author":"Kenison","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2022.102461_b0165","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1158\/0008-5472.CAN-07-6168","article-title":"Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells","volume":"68","author":"Hollingshead","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0170","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ctrv.2022.102461_b0175","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.18632\/oncotarget.1637","article-title":"Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR","volume":"5","author":"Litzenburger","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2022.102461_b0180","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2022.102461_b0185","doi-asserted-by":"crossref","first-page":"75407","DOI":"10.18632\/oncotarget.12249","article-title":"Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment","volume":"7","author":"Schafer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2022.102461_b0190","doi-asserted-by":"crossref","first-page":"e0146279","DOI":"10.1371\/journal.pone.0146279","article-title":"The role of indoleamine 2,3-dioxygenase in diethylnitrosamine-induced liver carcinogenesis","volume":"11","author":"Shibata","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2022.102461_b0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0200","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0205","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-cancerbio-030419-033635","article-title":"Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma?","volume":"4","author":"Van den Eynde","year":"2020","journal-title":"Ann Rev Cancer Biol"},{"key":"10.1016\/j.ctrv.2022.102461_b0210","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102461_b0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812822","article-title":"IDO1 inhibition reduces immune cell exclusion through inducing cell migration While PD-1 blockage increases IL-6 and -8 secretion from T cells in head and neck cancer","volume":"13","author":"Sievil\u00e4inen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2022.102461_b0220","doi-asserted-by":"crossref","unstructured":"Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Newton RC, Schaub R, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 2013;31:15_suppl, 3025-3025.","DOI":"10.1200\/jco.2013.31.15_suppl.3025"},{"key":"10.1016\/j.ctrv.2022.102461_b0225","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0230","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: Phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102461_b0235","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102461_b0240","unstructured":"https:\/\/ClinicalTrials.gov\/show\/NCT03322540. Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05\/ECHO-305-05). Accessed on Feb 27th, 2022."},{"key":"10.1016\/j.ctrv.2022.102461_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112373","article-title":"Discovery of indoximod prodrugs and characterization of clinical candidate NLG802","volume":"198","author":"Kumar","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ctrv.2022.102461_b0250","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.18632\/oncotarget.2357","article-title":"A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors","volume":"5","author":"Soliman","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2022.102461_b0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jamaoncol.2020.5572","article-title":"Effect of taxane chemotherapy with or without indoximod in metastatic breast cancer: a randomized clinical trial","volume":"7","author":"Mariotti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2022.102461_b0260","doi-asserted-by":"crossref","unstructured":"Siu LL, Gelmon K, Chu Q, Pachynski R, Alese O, Basciano P, et al. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1\/2a trial. Cancer Research. 2017;77:CT116.","DOI":"10.1158\/1538-7445.AM2017-CT116"},{"key":"10.1016\/j.ctrv.2022.102461_b0265","doi-asserted-by":"crossref","unstructured":"Tabernero J, Luke JJ, Joshua AM, Varga AI, Moreno V, Desai J, et al. BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC). Journal of Clinical Oncology. 2018;36:15_suppl, 4512-4512.","DOI":"10.1200\/JCO.2018.36.15_suppl.4512"},{"key":"10.1016\/j.ctrv.2022.102461_b0270","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2017.07.005","article-title":"A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer","volume":"146","author":"Kristeleit","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102461_b0275","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40425-019-0562-8","article-title":"Phase 1\/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma","volume":"7","author":"Gibney","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0280","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00262-018-2190-4","article-title":"Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"67","author":"Brown","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2022.102461_b0285","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/1535-7163.MCT-17-1104","article-title":"Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271\/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy","volume":"17","author":"Gomes","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2022.102461_b0290","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00262-019-02394-w","article-title":"Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy","volume":"68","author":"Zahm","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2022.102461_b0295","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002840","article-title":"Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation","volume":"9","author":"Qin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0300","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1038\/s41467-018-06951-2","article-title":"Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma","volume":"9","author":"Corre","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2022.102461_b0305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbrc.2008.07.156","article-title":"Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase","volume":"375","author":"Vogel","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ctrv.2022.102461_b0310","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"17","author":"Godin-Ethier","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0315","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","article-title":"Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors","volume":"20","author":"Conroy","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2022.102461_b0320","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s43018-021-00204-w","article-title":"Missing the target in cancer therapy","volume":"2","author":"Adashek","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0325","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0330","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4161\/onci.21358","article-title":"A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies","volume":"1","author":"Prendergast","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2022.102461_b0335","doi-asserted-by":"crossref","unstructured":"Zakharia Y, Rixe O, Ward JH, Drabick JJ, Shaheen MF, Milhem MM, et al. Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma. Journal of Clinical Oncology. 2018;36:5_suppl, 9512-9512.","DOI":"10.1200\/JCO.2018.36.15_suppl.9512"},{"key":"10.1016\/j.ctrv.2022.102461_b0340","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0345","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/CJI.0000000000000368","article-title":"A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer","volume":"44","author":"Kotecki","year":"2021","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2022.102461_b0350","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1535-7163.MCT-20-0251","article-title":"Preclinical characterization of linrodostat mesylate, a novel, potent, and selective oral indoleamine 2,3-dioxygenase 1 inhibitor","volume":"20","author":"Balog","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2022.102461_b0355","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/0008-5472.CAN-15-2011","article-title":"A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer","volume":"75","author":"D'Amato","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0360","article-title":"TDO2 promotes the EMT of hepatocellular carcinoma through Kyn-AhR pathway","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2022.102461_b0365","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2022.102461_b0370","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/cas.14797","article-title":"Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma","volume":"112","author":"Sumitomo","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2022.102461_b0375","doi-asserted-by":"crossref","first-page":"27584","DOI":"10.18632\/oncotarget.8488","article-title":"Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2\/kynurenine axis","volume":"7","author":"Hsu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2022.102461_b0380","doi-asserted-by":"crossref","unstructured":"Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg. 2009;208:781-7; discussion 7-9.","DOI":"10.1016\/j.jamcollsurg.2008.12.018"},{"key":"10.1016\/j.ctrv.2022.102461_b0385","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1016\/j.bmcl.2016.07.031","article-title":"1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)","volume":"26","author":"R\u00f6hrig","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ctrv.2022.102461_b0390","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00726-014-1766-3","article-title":"Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1","volume":"46","author":"Pantouris","year":"2014","journal-title":"Amino Acids"},{"key":"10.1016\/j.ctrv.2022.102461_b0395","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ejmech.2018.11.010","article-title":"Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase","volume":"162","author":"Winters","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ctrv.2022.102461_b0400","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.canlet.2021.09.012","article-title":"IDO1\/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer","volume":"522","author":"Liang","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2022.102461_b0405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000870","article-title":"Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0410","doi-asserted-by":"crossref","unstructured":"Capochiani de Iudicibus R, Tomek P, Palmer BD, Tijono SM, Flanagan JU, Ching LM. Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay. Bioorg Med Chem. 2021;39:116160.","DOI":"10.1016\/j.bmc.2021.116160"},{"key":"10.1016\/j.ctrv.2022.102461_b0415","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1158\/1541-7786.MCR-12-0216","article-title":"Ah receptor antagonism represses head and neck tumor cell aggressive phenotype","volume":"10","author":"DiNatale","year":"2012","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0420","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaw3306","article-title":"Kynurenine signaling through the aryl hydrocarbon receptor maintains the undifferentiated state of human embryonic stem cells","volume":"12","author":"Yamamoto","year":"2019","journal-title":"Sci Signal"},{"key":"10.1016\/j.ctrv.2022.102461_b0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678999","article-title":"IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation","volume":"12","author":"Amobi-McCloud","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2022.102461_b0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.625346","article-title":"Targeting the aryl hydrocarbon receptor signaling pathway in breast cancer development","volume":"12","author":"Vogel","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2022.102461_b0435","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1538-7445.AM2019-1288","article-title":"Abstract 1288: Blocking tumor-associated immune suppression with BAY-218, a novel, selective aryl hydrocarbon receptor (AhR) inhibitor","volume":"79","author":"Gutcher","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0440","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/2326-6066.CIR-16-0400","article-title":"Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance","volume":"5","author":"Hennequart","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0445","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/jnc.13503","article-title":"Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4","volume":"136","author":"Ochs","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.ctrv.2022.102461_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100396","article-title":"Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials","volume":"7","author":"Szeto","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2022.102461_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104998","article-title":"Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance","volume":"159","author":"Sandri","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0460","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1158\/2326-6066.CIR-20-0226","article-title":"IDO1 signaling through GCN2 in a subpopulation of Gr-1(+) cells shifts the IFN\u03b3\/IL6 balance to promote neovascularization","volume":"9","author":"Dey","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0465","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ebiom.2016.11.013","article-title":"IDO1 is an integral mediator of inflammatory neovascularization","volume":"14","author":"Mondal","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2022.102461_b0470","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1158\/1078-0432.CCR-21-1392","article-title":"Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0475","doi-asserted-by":"crossref","first-page":"1708065","DOI":"10.1080\/2162402X.2019.1708065","article-title":"Expression of TIM3\/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1\/PDL1 resistance: implications of immunogram heterogeneity","volume":"9","author":"Kato","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2022.102461_b0480","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jcyt.2016.05.010","article-title":"Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab","volume":"18","author":"Bjoern","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ctrv.2022.102461_b0485","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2022.102461_b0490","doi-asserted-by":"crossref","unstructured":"Naing A, Powderly JD, Falchook G, Creelan B, Nemunaitis J, Lutzky J, et al. Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I\/II ECHO-203 study. Cancer Research. 2018;78:CT177.","DOI":"10.1158\/1538-7445.AM2018-CT177"},{"key":"10.1016\/j.ctrv.2022.102461_b0495","doi-asserted-by":"crossref","unstructured":"Daud A, Saleh MN, Hu J, Bleeker JS, Riese MJ, Meier R, et al. Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study. Journal of Clinical Oncology. 2018;36:15_suppl, 9511-9511.","DOI":"10.1200\/JCO.2018.36.15_suppl.9511"},{"key":"10.1016\/j.ctrv.2022.102461_b0500","doi-asserted-by":"crossref","unstructured":"Kelly CM, Chi P, Dickson MA, Gounder MM, Keohan ML, Qin L-X, et al. A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma. Journal of Clinical Oncology. 2019;37:15_suppl, 11049-11049.","DOI":"10.1200\/JCO.2019.37.15_suppl.11049"},{"key":"10.1016\/j.ctrv.2022.102461_b0505","doi-asserted-by":"crossref","unstructured":"Tanyi JL, Dorigo O, Oza AM, Strauss JF, Pejovic T, Ghamande SA, et al. DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression. Journal of Clinical Oncology. 2019;37:15_suppl, 5576-5576.","DOI":"10.1200\/JCO.2019.37.15_suppl.5576"},{"key":"10.1016\/j.ctrv.2022.102461_b0510","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.32951","article-title":"Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer","volume":"147","author":"Hellmann","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2022.102461_b0515","doi-asserted-by":"crossref","unstructured":"Doi T, Fujiwara Y, Shitara K, Shimizu T, Yonemori K, Matsubara N, et al. The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). Invest New Drugs. 2021;39:152-62.","DOI":"10.1007\/s10637-020-00942-1"},{"key":"10.1016\/j.ctrv.2022.102461_b0520","doi-asserted-by":"crossref","unstructured":"Jackson E, Dees EC, Kauh JS, Harvey RD, Neuger A, Lush R, et al. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. Journal of Clinical Oncology. 2013;31:15_suppl, 3026-3026.","DOI":"10.1200\/jco.2013.31.15_suppl.3026"},{"key":"10.1016\/j.ctrv.2022.102461_b0525","doi-asserted-by":"crossref","unstructured":"Colman H, Mott F, Spira AI, Johnson TS, Zakharia Y, Vahanian NN, et al. A phase 1b\/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component. Journal of Clinical Oncology. 2015;33:15_suppl, 2070-2070.","DOI":"10.1200\/jco.2015.33.15_suppl.2070"},{"key":"10.1016\/j.ctrv.2022.102461_b0530","doi-asserted-by":"crossref","unstructured":"Jha GG, Gupta S, Tagawa ST, Koopmeiners JS, Vivek S, Dudek AZ, et al. A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2017;35:15_suppl, 3066-3066.","DOI":"10.1200\/JCO.2017.35.15_suppl.3066"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2022.102461_b0535","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood-2018-99-117433","article-title":"Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial","volume":"132","author":"Emadi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102461_b0540","doi-asserted-by":"crossref","unstructured":"Bahary N, Wang-Gillam A, Haraldsdottir S, Somer BG, Lee JS, O'Rourke MA, et al. Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine \/ nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. Journal of Clinical Oncology. 2018;36:15_suppl, 4015-4015.","DOI":"10.1200\/JCO.2018.36.15_suppl.4015"},{"key":"10.1016\/j.ctrv.2022.102461_b0545","doi-asserted-by":"crossref","first-page":"10110","DOI":"10.18632\/oncotarget.24118","article-title":"A phase-1\/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer","volume":"9","author":"Soliman","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2022.102461_b0550","doi-asserted-by":"crossref","unstructured":"Luke JJ, Gelmon K, Pachynski RK, Desai J, Moreno V, Tabernero JM, et al. O41 Preliminary antitumor and immunomodulatory activity of BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, in combination with nivolumab in patients with advanced cancers. 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts. Journal for ImmunoTherapy of Cancer. 2017;5:89.","DOI":"10.1186\/s40425-017-0297-3"},{"key":"10.1016\/j.ctrv.2022.102461_b0555","doi-asserted-by":"crossref","unstructured":"Luke JJ, Tabernero J, Joshua A, Desai J, Varga AI, Moreno V, et al. BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC). Journal of Clinical Oncology. 2019;37:7_suppl, 358-358.","DOI":"10.1200\/JCO.2019.37.7_suppl.358"},{"key":"10.1016\/j.ctrv.2022.102461_b0560","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s10637-020-00950-1","article-title":"A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma","volume":"38","author":"Reardon","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2022.102461_b0565","doi-asserted-by":"crossref","unstructured":"Desai P, Rao S, Ikawa Y, Kapelan B, Efuni S, Latek R, et al. Abstract CT238: An open-label, phase 1 study of IDO inhibitor KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma. Cancer Research. 2020;80:CT238.","DOI":"10.1158\/1538-7445.AM2020-CT238"},{"key":"10.1016\/j.ctrv.2022.102461_b0570","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3101","article-title":"A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with\/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis","volume":"39","author":"Cheng","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2022.102461_b0575","unstructured":"https:\/\/ClinicalTrials.gov\/show\/NCT03364049. Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002). Accessed on Feb 27th, 2022."},{"key":"10.1016\/j.ctrv.2022.102461_b0580","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1078-0432.CCR-13-1560","article-title":"Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase","volume":"20","author":"Iversen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102461_b0585","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3389\/fimmu.2018.02145","article-title":"Durable clinical responses and long-term follow-up of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study-a brief research report","volume":"9","author":"Kjeldsen","year":"2018","journal-title":"Front Immunol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722200130X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722200130X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:57Z","timestamp":1759656477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722200130X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":117,"alternative-id":["S030573722200130X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102461","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102461"}}